But if the relative expression of TNRC6B is > 5.618 and the relative expression of CDK6 is ≤ 2.841, patients can be classified as high-risk PCa, concretely, 2.4% of subjects can be correctly advanced the presence of an aggressive tumour (Fig. 5e). The gene discussed is TNRC6B; the disease is posterior cortical atrophy.